1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ALIVUS LIFE SCIENCES LTD.
Alivus Life Sciences Ltd.
NSE: ALIVUS | BSE: 543322
Strong Performer, Getting Expensive
Download real time
Ask AI about Alivus Life Sciences
1373.80-0.40(-0.03%)
67.74% Gain from 52W Low
100.1K
NSE+BSE Volume

NSE 05 Oct, 2026 3:29 PM (IST)

Portfolio

Alert

My Notes

Alivus Life Sciences quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Alivus Life Sciences share price target, revenues, EPS, net income and more

Alivus Life Sciences quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Alivus Life Sciences Jun-2026 Quarterly Revenue is Rs 663 Cr which is growth of 8.5% YoY.

  • POSITIVE

    Quarterly Net Profit Alivus Life Sciences Jun-2026 Quarterly Net Profit is Rs 160 Cr which is growth of 31.7% YoY.

Alivus Life Sciences Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
⌄
662.8711.9686.8602.7610.8659.6652.3515.4594.1539.7574.5600.7580.3
Operating Exp.
428.7474.6441.6408.8429.5451.1451.5372.5429.1395.2400.3428.3385.3
Operating Profit
211.7214.5231.3179.2172.3198.4190.3134.4159.5141.5172.6167.1193.2
Operating Profit Margin %
33.06%31.13%34.37%30.47%28.63%30.55%29.65%26.51%27.09%26.36%30.12%28.06%33.39%
Depr.
20.620.219.718.417.11615.215.114.414.513.213.112.6
Interest
1.31.31.51.31.31.30.50.30.40.40.40.40.4
Profit Before Tax
212.2215.8198.4174.1163191.3185.2127.5150.2129.7160.7158.9182
Tax
52.253.148.144.141.549.448.232.138.831.741.940.246.6
Net Profit
160.1162.7150.3130121.5141.913795.3111.597.9118.8118.7135.5
EPS Adj. latest
1313.312.210.69.911.611.27.89.189.79.711
Net profit TTM
603564.5543.7530.4495.7485.6441.7423.5446.9470.9519.3505.5493.7
Basic EPS TTM
49.14644.343.240.439.636.134.636.538.442.441.340.3
Earnings Transcripts
AI Summary
   
  
   
Results PDF
  
Result Notes
Notes
Notes
Notes
Notes
Notes
 
Notes
Notes
Notes
Notes
Notes
Notes
Notes
*All financials are in INR Cr and price data in INR
Add metric to table
Search...

Alivus Life Sciences competitor comparison and performance snapshot within industry

Alivus Life Sciences annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Alivus Life Sciences Mar-2026 Annual Revenue is Rs 2,612 Cr which is growth of 7.9% YoY.

  • POSITIVE

    Annual Net Profit Alivus Life Sciences Mar-2026 Annual Net Profit is Rs 564 Cr which is growth of 16.2% YoY.

Alivus Life Sciences Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18
⌄
6%
6.7%
2,664.22,612.22,421.52,295.32,190.22,137.91,8861,549.3886.90.3
Operating Exp. Ann.
4.9%
6.3%
1,753.71,754.61,704.31,6091,518.91,507.21,294.11,065.4638.70.3
Operating Profit Ann.
7.5%
6.2%
836.7797.3682.6674.3642.3616.1591.1472247.7-0
OPM Ann. %
1.3%
-0.5%
 30.52%28.19%29.38%29.33%28.82%31.34%30.46%27.93%-5.65%
⌄
5.5%
5.3%
 1,835.31,767.31,6641,561.61,5731,4151,128.2658.60.3
EBITDA Ann.
8.5%
7.7%
 857.7717.2686.3671.3630.8591.9484248.2-0
EBITDA Ann. margin %
2.3%
0.9%
 32.83%29.62%29.90%30.65%29.50%31.38%31.24%27.98%-5.65%
Interest Ann.
108%
-42.7%
5.45.42.41.60.62887.633.50.6
Depr.
21.4%
17.7%
78.975.460.653.542.137.933.429.419.3
PBT Ann.
6.1%
9.8%
800.6751.3654.1631.3628.6564.9470.9421.1228.3-0
Tax Ann.
4.9%
9.4%
197.5186.8168.5160.4161.7146.2119.410832.70.4
⌄
6.5%
9.9%
 564.5485.6470.9467418.7351.6313.1195.6-0.4
Net Profit Ann.
6.5%
9.9%
603564.5485.6470.9467418.7351.6313.1195.6-0.4
NPM Ann. %
0.8%
3.5%
 22.12%20.34%20.62%21.60%19.72%18.64%20.36%22.06%-175.40%
EPS Adj. latest Ann.
6.6%
10%
 4639.638.43834.128.625.515.9-0
Result Notes
 
Notes
 
Notes
Notes
Notes
    
Annual Reports
     
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
7.9%
2Y CAGR
6.7%
3Y CAGR
6%
5Y CAGR
6.7%
7Y CAGR
16.7%
Total Revenue Annual growth is stable compared to historical averages.
Net Profit Ann.
1Y CHG
16.2%
2Y CAGR
9.5%
3Y CAGR
6.5%
5Y CAGR
9.9%
7Y CAGR
16.3%
Net Profit Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
3%
2Y CAGR
4.4%
3Y CAGR
4.9%
5Y CAGR
6.3%
7Y CAGR
15.5%
Operating Expenses Annual Cr growth is lower than historical averages.

Alivus Life Sciences balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Alivus Life Sciences Mar-2026 Total Shareholders Fund is Rs 3,332 Cr which is growth of 18.3% YoY.

  • POSITIVE

    Total Assets Alivus Life Sciences Mar-2026 Total Assets is Rs 3,983 Cr which is growth of 16.8% YoY.

Alivus Life Sciences Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18
⌄
15.9%
34.7%
3,332.12,817.42,332.32,138.22,054.3752.8401.788.1-1.4
Minority Interest Liability Ann.
-
-
---------
⌄
33.9%
44.2%
142.7123.979.359.532.722.916.56.9
⌄
0.2%
-16.1%
508470.2438.8504.43841,221.41,307.51,380.41.5
Total Capital Plus Liabilities Ann.
13.8%
14.8%
3,982.93,411.52,850.42,702.22,4711,997.11,725.61,475.40.1
⌄
16.2%
17.6%
1,321.31,056.9911.1842.2686.7586.9557536.7
⌄
16.1%
17.4%
1,333.51,076.3934.4851.8706.4598565.5544.7
⌄
12.7%
13.6%
2,649.42,335.21,9161,850.31,764.61,3991,160.1930.70.1
Total Assets Ann.
13.8%
14.8%
3,982.93,411.52,850.42,702.22,4711,997.11,725.61,475.40.1
Contingent Liabilities plus Commitments Ann.
105.1%
45.1%
110.537.934.212.850.417.238.9187.3
Bonus Equity Share Capital Ann.
0%
-
19.619.619.619.619.6
Non Current Investments Unquoted Book Value Ann.
0%
0%
0.10.10.10.10.10.10.10.1
Current Investments Unquoted Book Value Ann.
-
-
780.4477.6
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
16.7%
2Y CAGR
18.2%
3Y CAGR
13.8%
5Y CAGR
14.8%
7Y CAGR
15.2%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
8%
2Y CAGR
7.6%
3Y CAGR
0.2%
5Y CAGR
-16.1%
7Y CAGR
-13.3%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
18.3%
2Y CAGR
19.5%
3Y CAGR
15.9%
5Y CAGR
34.7%
7Y CAGR
68%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Alivus Life Sciences ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Alivus Life Sciences Mar-2026 Book Value Per Share is 271 Rs which is growth of 18.1% YoY.

  • POSITIVE

    ROE Alivus Life Sciences Mar-2026 ROE is 17% which is growth of 0.3% YoY.

Alivus Life Sciences Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18
BVSH Ann.
15.9%
-18.8%
271.5229.9190.4174.5167.7768.12,049.51,883.2-1,398
RoA Ann. %
-6.4%
-4.2%
14.17%14.23%16.51%17.28%16.94%17.60%18.14%13.25%-517.85%
ROE Ann. %
-8.1%
-18.4%
16.94%17.23%20.18%21.83%20.38%46.70%77.94%225.79%
ROCE Ann. %
-7.7%
-20.7%
22.51%22.32%26.24%28.62%28.40%72.00%108.71%240.99%1.00%
⌄
         
⌄
         
⌄
         
Total Debt to Total Equity Ann.
         
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
ROE Ann. %
1Y CHG
-1.7%
2Y CAGR
-8.4%
3Y CAGR
-8.1%
5Y CAGR
-18.4%
7Y CAGR
-30.9%
ROE Annual % is falling slower than historical averages.
RoA Ann. %
1Y CHG
-0.4%
2Y CAGR
-7.4%
3Y CAGR
-6.4%
5Y CAGR
-4.2%
7Y CAGR
1%
RoA Annual % is falling faster than historical averages.
Current Ratio Ann.
1Y CHG
4%
2Y CAGR
8.7%
3Y CAGR
12%
5Y CAGR
34.1%
7Y CAGR
33.2%
Current Ratio Annual growth is lower than historical averages.

Alivus Life Sciences cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Alivus Life Sciences Mar-2026 Cash From Operating Activity is Rs 565 Cr which is growth of 44.4% YoY.

  • POSITIVE

    Net Cash Flow Alivus Life Sciences Mar-2026 Net Cash Flow is Rs -69 Cr which is growth of 70.0% YoY.

Alivus Life Sciences Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18
⌄
21.7%
7.8%
565.4391.5413.5313.4597.6388.119510.4-0.5
Cash from Investing Act. Ann.
-
-
-570.2-615.6-116.5-154.1-122.2-68.7-50.5-8.9
Cash from Financing Act. Ann.
-
-
-64.3-6.2-279.4-387.6-78.8-213.8-136.60.50.5
⌄
-
-
-69.1-230.417.6-228.3396.6105.67.92
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
44.4%
2Y CAGR
16.9%
3Y CAGR
21.7%
5Y CAGR
7.8%
7Y CAGR
77%
Cash from Operating Activity Annual growth is stable compared to historical averages.

Alivus Life Sciences investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Ask AI
×